Is EMOTIONAL DISTRESS a side effect of SORAFENIB (RAF KINASE INHIBITOR) ? ( FactMed.com )

About this FactMed analysis covering adverse side effect reports of SORAFENIB (RAF KINASE INHIBITOR) patients who developed EMOTIONAL DISTRESS.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 2 individuals taking SORAFENIB (RAF KINASE INHIBITOR) reported EMOTIONAL DISTRESS to the FDA. A total of 3329 SORAFENIB (RAF KINASE INHIBITOR) drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between SORAFENIB (RAF KINASE INHIBITOR) and EMOTIONAL DISTRESS. In doing so, we compare SORAFENIB (RAF KINASE INHIBITOR) with other drugs that cause EMOTIONAL DISTRESS, to help you evaluate whether or not SORAFENIB (RAF KINASE INHIBITOR) causes EMOTIONAL DISTRESS. Likewise, this page shows the most highly-reported side effects of SORAFENIB (RAF KINASE INHIBITOR), so you can see if EMOTIONAL DISTRESS ranks among SORAFENIB (RAF KINASE INHIBITOR)'s most well-known side effects.

Summary Statistics
Reports of SORAFENIB (RAF KINASE INHIBITOR) causing EMOTIONAL DISTRESS: 2
Reports of any side effect of SORAFENIB (RAF KINASE INHIBITOR) : 3329
Percentage of SORAFENIB (RAF KINASE INHIBITOR) patients where EMOTIONAL DISTRESS is a reported side effect: 0.0601%

FDA reports of any drug causing EMOTIONAL DISTRESS : 31645
Average percentage for all medicated patients where EMOTIONAL DISTRESS is reported as a complication: 0.1983%

Physician opinion on SORAFENIB (RAF KINASE INHIBITOR) as adverse event culprit:

Overall opinion for all reports of this drug:

Most frequent diagnoses/indications for prescribing SORAFENIB (RAF KINASE INHIBITOR):

HEPATIC NEOPLASM MALIGNANT ( 770 patients )
RENAL CELL CARCINOMA ( 114 patients )
THYROID CANCER ( 65 patients )
METASTATIC RENAL CELL CARCINOMA ( 44 patients )
THYROID CANCER METASTATIC ( 35 patients )
BREAST CANCER ( 31 patients )
BREAST CANCER METASTATIC ( 27 patients )
GASTRIC CANCER ( 25 patients )
NON-SMALL CELL LUNG CANCER ( 25 patients )
COLORECTAL CANCER METASTATIC ( 22 patients )
RENAL CANCER ( 17 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 14 patients )
BILE DUCT CANCER ( 14 patients )
SALIVARY GLAND CANCER ( 7 patients )
HEPATIC CANCER METASTATIC ( 7 patients )
COLORECTAL CANCER ( 7 patients )
SMALL CELL LUNG CANCER STAGE UNSPECIFIED ( 6 patients )
RECTAL CANCER ( 5 patients )
PANCREATIC CARCINOMA ( 4 patients )
PROSTATE CANCER ( 4 patients )
INTRAOCULAR MELANOMA ( 4 patients )
HEPATIC NEOPLASM MALIGNANT RECURRENT ( 3 patients )
NEOPLASM ( 3 patients )
LIVER DISORDER ( 3 patients )
ANGIOSARCOMA ( 3 patients )
NON-SMALL CELL LUNG CANCER STAGE IV ( 3 patients )
METASTASES TO LUNG ( 3 patients )
HEPATIC NEOPLASM MALIGNANT NON-RESECTABLE ( 3 patients )
COLORECTAL CANCER STAGE IV ( 3 patients )
NEOPLASM MALIGNANT ( 3 patients )
GALLBLADDER CANCER METASTATIC ( 3 patients )
METASTASIS ( 3 patients )
BILIARY CANCER METASTATIC ( 3 patients )
COLON CANCER METASTATIC ( 2 patients )
HYPOPHARYNGEAL CANCER ( 2 patients )
DESMOID TUMOUR ( 2 patients )
NEUROENDOCRINE CARCINOMA ( 2 patients )
LUNG NEOPLASM MALIGNANT ( 2 patients )
ACUTE MYELOID LEUKAEMIA (IN REMISSION) ( 2 patients )
OESOPHAGEAL CARCINOMA ( 2 patients )
METASTATIC MALIGNANT MELANOMA ( 2 patients )
TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED ( 2 patients )
METASTATIC SQUAMOUS CELL CARCINOMA ( 2 patients )
RENAL CELL CARCINOMA STAGE IV ( 2 patients )
ANGINA PECTORIS ( 2 patients )
OSTEOSARCOMA METASTATIC ( 2 patients )
METASTATIC OCULAR MELANOMA ( 2 patients )
BONE SARCOMA ( 2 patients )
METASTATIC SALIVARY GLAND CANCER ( 2 patients )
TONSIL CANCER ( 2 patients )
MYELODYSPLASTIC SYNDROME ( 1 patients )
PROSTATE CANCER METASTATIC ( 1 patients )
GALLBLADDER CANCER ( 1 patients )
NEUROENDOCRINE TUMOUR ( 1 patients )
MALIGNANT NEOPLASM OF RENAL PELVIS ( 1 patients )
GLIOMA ( 1 patients )
BLADDER CANCER ( 1 patients )
OVARIAN CANCER METASTATIC ( 1 patients )
CAROTID ARTERY DISEASE ( 1 patients )
HEPATOBLASTOMA ( 1 patients )
NASOPHARYNGEAL CANCER ( 1 patients )
LUNG ADENOCARCINOMA ( 1 patients )
RENAL CANCER METASTATIC ( 1 patients )
ACUTE MYELOID LEUKAEMIA ( 1 patients )
DIFFUSE LARGE B-CELL LYMPHOMA ( 1 patients )
NEUROENDOCRINE CARCINOMA OF THE SKIN ( 1 patients )
MALIGNANT HISTIOCYTOSIS ( 1 patients )
MALIGNANT SOFT TISSUE NEOPLASM ( 1 patients )
SARCOMA ( 1 patients )
ANTICOAGULANT THERAPY ( 1 patients )
GERM CELL CANCER ( 1 patients )
OESOPHAGEAL ADENOCARCINOMA ( 1 patients )
SQUAMOUS CELL CARCINOMA ( 1 patients )
HEAD AND NECK CANCER ( 1 patients )
OVARIAN EPITHELIAL CANCER ( 1 patients )
( 0 patients )

Drugs with high FDA adverse event association with EMOTIONAL DISTRESS:

TRASYLOL (9561 patients)
YAZ (7219 patients)
YASMIN (6871 patients)
VIOXX (5899 patients)
ZOMETA (2873 patients)
LASIX (2648 patients)
HEPARIN (2600 patients)
ASPIRIN (2544 patients)
DROSPIRENONE AND ETHINYL ESTRADIOL (2439 patients)
MAGNEVIST (2324 patients)
ACCUTANE (2031 patients)
METOCLOPRAMIDE (1813 patients)
AREDIA (1628 patients)
LIPITOR (1533 patients)
OMNISCAN (1526 patients)
NITROGLYCERIN (1520 patients)
COUMADIN (1457 patients)
LISINOPRIL (1373 patients)
PROTAMINE SULFATE (1327 patients)
MIRAPEX (1274 patients)
FOSAMAX (1257 patients)
NEURONTIN (1237 patients)
NEXIUM (1234 patients)
IBUPROFEN (1164 patients)
PROTONIX (1136 patients)
ACETYLSALICYLIC ACID SRT (1132 patients)
PREDNISONE (1132 patients)
RED BLOOD CELLS (1088 patients)
PLAVIX (1087 patients)
OPTIMARK (1066 patients)
AMBIEN (1054 patients)
VERSED (1049 patients)
NORVASC (1026 patients)
SYNTHROID (1016 patients)
ZOCOR (1015 patients)
FENTANYL (1013 patients)
VICODIN (1012 patients)
VANCOMYCIN (1004 patients)
CELEBREX (999 patients)
PRILOSEC (997 patients)
XANAX (976 patients)
DIGOXIN (969 patients)
LEVAQUIN (962 patients)
ZOLOFT (957 patients)
INSULIN (933 patients)
ATENOLOL (912 patients)
CHANTIX (908 patients)
ATIVAN (901 patients)
MULTIHANCE (884 patients)
PAXIL (882 patients)
ALBUTEROL (878 patients)
HYDROCHLOROTHIAZIDE (876 patients)
PROHANCE (872 patients)
OXYCONTIN (852 patients)
PREVACID (822 patients)
PERCOCET (806 patients)
TOPROL-XL (796 patients)
FUROSEMIDE (784 patients)
LEXAPRO (780 patients)
LOPRESSOR (759 patients)
AMOXICILLIN (756 patients)
PLATELETS (699 patients)
COREG (683 patients)
POTASSIUM CHLORIDE (682 patients)
ACETAMINOPHEN (646 patients)
MANNITOL (642 patients)
SEROQUEL (641 patients)
LIDOCAINE (640 patients)
LORTAB (628 patients)
ANCEF (611 patients)
GABAPENTIN (609 patients)
LORAZEPAM (603 patients)
ZITHROMAX (593 patients)
DEXAMETHASONE (590 patients)
METOPROLOL TARTRATE (588 patients)
EPINEPHRINE (583 patients)
LOVENOX (570 patients)
REGLAN (570 patients)
DOPAMINE HCL (558 patients)
ZOFRAN (551 patients)
ZANTAC (546 patients)
FLEXERIL (544 patients)
CHEMOTHERAPEUTICS NOS (543 patients)
DECADRON (540 patients)
OXYCODONE HCL (539 patients)
CYMBALTA (538 patients)
EPOGEN (532 patients)
EFFEXOR (531 patients)
WELLBUTRIN (530 patients)
CELEXA (530 patients)
MORPHINE (530 patients)
ADVAIR DISKUS 100/50 (523 patients)
ZYRTEC (519 patients)
DIOVAN (518 patients)
MOTRIN (517 patients)
AMIODARONE HCL (516 patients)
PROZAC (515 patients)
FOLIC ACID (491 patients)
SIMVASTATIN (487 patients)
OMEPRAZOLE (481 patients)
CEPHALEXIN (480 patients)
ALLOPURINOL (476 patients)
CLINDAMYCIN (474 patients)
NAPROXEN (471 patients)
ALPRAZOLAM (471 patients)
PREMARIN (458 patients)
FEMARA (454 patients)
GADOLINIUM IN UNSPECIFIED DRUG (453 patients)
DEPAKOTE (448 patients)
CALCIUM (447 patients)
AVANDIA (447 patients)
KLONOPIN (431 patients)
FRESH FROZEN PLASMA (427 patients)
LEVOTHYROXINE SODIUM (424 patients)
ARANESP (418 patients)
LYRICA (416 patients)
DILAUDID (416 patients)
COLACE (413 patients)
PERIDEX (412 patients)
FLONASE (411 patients)
THALIDOMIDE (406 patients)
AZITHROMYCIN (402 patients)
MULTI-VITAMINS (401 patients)
METFORMIN HCL (393 patients)
GLUCOPHAGE (392 patients)
TYLENOL (387 patients)
LEVOPHED (387 patients)
CLONIDINE (385 patients)
PROPOFOL (384 patients)
ZESTRIL (381 patients)
ALBUMIN (HUMAN) (381 patients)
WARFARIN SODIUM (379 patients)
TAMOXIFEN CITRATE (378 patients)
SINGULAIR (377 patients)
TAXOTERE (377 patients)
COZAAR (376 patients)
ULTRAM (374 patients)
HYDROCODONE BITARTRATE (372 patients)
ALTACE (369 patients)
CHLORHEXIDINE GLUCONATE (367 patients)
BENADRYL (366 patients)
CIPROFLOXACIN (363 patients)
SPIRONOLACTONE (361 patients)
PEPCID (360 patients)
MILRINONE (358 patients)
COMPAZINE (357 patients)
ALLEGRA (354 patients)
METOPROLOL (354 patients)
CLARITIN (353 patients)
LANTUS (352 patients)
TYLENOL (CAPLET) (349 patients)
PREDNISONE TAB (348 patients)
SODIUM BICARBONATE (343 patients)
CLONAZEPAM (342 patients)
HYDROCODONE (339 patients)
DIAZEPAM (336 patients)
RENAGEL (334 patients)
GLIPIZIDE (332 patients)
ASCORBIC ACID (330 patients)
MORPHINE SULFATE (323 patients)
CEFAZOLIN (321 patients)
DOXYCYCLINE (320 patients)
OCELLA (319 patients)
EFFEXOR XR (319 patients)
ARIMIDEX (318 patients)
FLUCONAZOLE (318 patients)
ACTOS (312 patients)
MULTI-VITAMIN (311 patients)
METRONIDAZOLE (310 patients)
CALCIUM CHLORIDE (308 patients)
CONTRAST MEDIA (306 patients)
IMDUR (305 patients)
[THERAPY UNSPECIFIED] (305 patients)
CARDIZEM (304 patients)
AUGMENTIN '125' (300 patients)
PRAVACHOL (300 patients)
XELODA (300 patients)
DURAGESIC-100 (299 patients)
KLOR-CON (297 patients)
SKELAXIN (294 patients)
VALIUM (292 patients)
CIPRO (292 patients)
GLYBURIDE (292 patients)
VITAMIN D (289 patients)
AVELOX (288 patients)
CALCIUM CARBONATE (286 patients)
ACIPHEX (281 patients)
KEFLEX (277 patients)
PROMETHAZINE (276 patients)
TRAZODONE HCL (271 patients)
ELAVIL (270 patients)
MS CONTIN (270 patients)
MAGNESIUM SULFATE (269 patients)
ENALAPRIL MALEATE (269 patients)
REVLIMID (266 patients)
VITAMIN E (265 patients)
FASLODEX (264 patients)
CRESTOR (264 patients)
HYDROCODONE BITARTRATE AND ACETAMINOPHEN (262 patients)
PROCRIT /00909301/ (260 patients)
SOLU-MEDROL (260 patients)
LANOXIN (260 patients)
METHOTREXATE (259 patients)
DIFLUCAN (259 patients)
CYTOXAN (258 patients)
ZETIA (258 patients)
TOPAMAX (258 patients)
FLAGYL (257 patients)
PHENYLEPHRINE HCL (256 patients)
TEMAZEPAM (255 patients)

Most common side effects for patients taking SORAFENIB (RAF KINASE INHIBITOR):

DIARRHOEA (613 patients)
HEPATIC FAILURE (378 patients)
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME (342 patients)
HEPATIC ENCEPHALOPATHY (320 patients)
FATIGUE (300 patients)
RASH (276 patients)
ASCITES (253 patients)
ABDOMINAL PAIN (237 patients)
DECREASED APPETITE (226 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (198 patients)
PYREXIA (191 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (179 patients)
NAUSEA (165 patients)
HYPERTENSION (160 patients)
ASTHENIA (154 patients)
DEHYDRATION (140 patients)
HEPATIC FUNCTION ABNORMAL (133 patients)
DYSPNOEA (131 patients)
CONFUSIONAL STATE (131 patients)
HYPOKALAEMIA (125 patients)
ALOPECIA (124 patients)
VOMITING (118 patients)
CONSTIPATION (115 patients)
INTERSTITIAL LUNG DISEASE (114 patients)
LEFT VENTRICULAR DYSFUNCTION (113 patients)
DEATH (113 patients)
ENDOCARDITIS (112 patients)
ARTHRALGIA (111 patients)
STOMATITIS (111 patients)
ABDOMINAL PAIN UPPER (110 patients)
JAUNDICE (108 patients)
HEPATIC NEOPLASM MALIGNANT (106 patients)
GASTROINTESTINAL HAEMORRHAGE (106 patients)
RETINAL VASCULAR THROMBOSIS (103 patients)
LOWER GASTROINTESTINAL HAEMORRHAGE (103 patients)
LIVER CARCINOMA RUPTURED (101 patients)
OEDEMA PERIPHERAL (97 patients)
PLEURAL EFFUSION (97 patients)
STAPHYLOCOCCAL INFECTION (96 patients)
PNEUMONIA BACTERIAL (96 patients)
ENTEROBACTER INFECTION (96 patients)
MYOPATHY (95 patients)
DRY MOUTH (94 patients)
PAIN IN EXTREMITY (93 patients)
ANXIETY (90 patients)
MALAISE (89 patients)
PULMONARY EMBOLISM (85 patients)
ANAEMIA (84 patients)
PLATELET COUNT DECREASED (81 patients)
BACK PAIN (79 patients)
SEPSIS (78 patients)
PRURITUS (78 patients)
DUODENAL ULCER (77 patients)
MIGRAINE (76 patients)
MITRAL VALVE INCOMPETENCE (76 patients)
HYPOGLYCAEMIA (76 patients)
C-REACTIVE PROTEIN INCREASED (74 patients)
BLOOD PRESSURE INCREASED (73 patients)
VARICES OESOPHAGEAL (73 patients)
HEADACHE (72 patients)
RETINAL VEIN OCCLUSION (72 patients)
ABASIA (69 patients)
RENAL FAILURE ACUTE (69 patients)
WEIGHT DECREASED (67 patients)
DEEP VEIN THROMBOSIS (67 patients)
DIZZINESS (65 patients)
ERYTHEMA (65 patients)
GENERAL PHYSICAL HEALTH DETERIORATION (64 patients)
CONVULSION (63 patients)
ALANINE AMINOTRANSFERASE INCREASED (62 patients)
DYSPHONIA (62 patients)
CEREBRAL HAEMORRHAGE (60 patients)
APHAGIA (58 patients)
COLITIS (58 patients)
PNEUMONIA (57 patients)
GASTRIC ULCER (56 patients)
HYPONATRAEMIA (55 patients)
HAEMOGLOBIN DECREASED (53 patients)
RESPIRATORY FAILURE (52 patients)
LUNG DISORDER (52 patients)
CEREBRAL ISCHAEMIA (49 patients)
PARAESTHESIA (49 patients)
BLOOD BILIRUBIN INCREASED (48 patients)
GAIT DISTURBANCE (48 patients)
THYROID CANCER METASTATIC (44 patients)
DEPRESSED LEVEL OF CONSCIOUSNESS (43 patients)
PERICARDIAL EFFUSION (41 patients)
THROMBOCYTOPENIA (41 patients)
BLISTER (41 patients)
FEBRILE NEUTROPENIA (40 patients)
BLOOD LACTATE DEHYDROGENASE INCREASED (40 patients)
HALLUCINATION (40 patients)
CHILLS (40 patients)
AMMONIA INCREASED (39 patients)
SKIN ULCER (39 patients)
BLOOD ALKALINE PHOSPHATASE INCREASED (38 patients)
PAIN (38 patients)
HYPOALBUMINAEMIA (38 patients)
HYPOCALCAEMIA (37 patients)
FALL (37 patients)
POLLAKIURIA (37 patients)
BLOOD PRESSURE DECREASED (37 patients)
SKIN EXFOLIATION (37 patients)
INSOMNIA (36 patients)
CARDIAC ARREST (36 patients)
HYPOAESTHESIA (35 patients)
INFECTIOUS PERITONITIS (35 patients)
MYOCARDIAL INFARCTION (35 patients)
RETINAL VASCULAR DISORDER (34 patients)
RENAL FAILURE (34 patients)
LIPASE INCREASED (34 patients)
HYPERKALAEMIA (33 patients)
HYPERGLYCAEMIA (33 patients)
HAEMOPTYSIS (31 patients)
ATRIAL FIBRILLATION (30 patients)
GENERALISED OEDEMA (30 patients)
FAECAL INCONTINENCE (30 patients)
WHITE BLOOD CELL COUNT DECREASED (30 patients)
CELLULITIS (29 patients)
CHEST PAIN (29 patients)
SOMNOLENCE (29 patients)
HYPERBILIRUBINAEMIA (28 patients)
HYPOTENSION (28 patients)
MUSCLE SPASMS (28 patients)
ABDOMINAL DISTENSION (27 patients)
WHITE BLOOD CELL COUNT INCREASED (27 patients)
VISION BLURRED (27 patients)
HEPATIC PAIN (26 patients)
BLOOD ALBUMIN DECREASED (26 patients)
DYSURIA (25 patients)
RASH GENERALISED (25 patients)
BLOOD SODIUM DECREASED (25 patients)
BLOOD URIC ACID INCREASED (25 patients)
COMA (25 patients)
COUGH (25 patients)
PANCYTOPENIA (25 patients)
ACUTE ABDOMEN (24 patients)
EOSINOPHIL COUNT INCREASED (24 patients)
CEREBROVASCULAR ACCIDENT (24 patients)
METASTASES TO CENTRAL NERVOUS SYSTEM (23 patients)
CEREBRAL INFARCTION (23 patients)
HYPOMAGNESAEMIA (23 patients)
RETINAL VEIN THROMBOSIS (23 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (23 patients)
TUMOUR LYSIS SYNDROME (22 patients)
HYPOPHOSPHATAEMIA (22 patients)
INFECTION (22 patients)
ORAL PAIN (22 patients)
BLOOD CREATININE INCREASED (22 patients)
NEUTROPENIA (22 patients)
RENAL IMPAIRMENT (22 patients)
LETHARGY (22 patients)
SKIN TOXICITY (21 patients)
TONGUE BLISTERING (21 patients)
LIVER ABSCESS (21 patients)
HAEMATEMESIS (21 patients)
OESOPHAGEAL VARICES HAEMORRHAGE (20 patients)
MENTAL IMPAIRMENT (20 patients)
NERVOUSNESS (20 patients)
NEPHROTIC SYNDROME (20 patients)
HYPOPHAGIA (20 patients)
ADRENAL INSUFFICIENCY (19 patients)
DRY SKIN (19 patients)
BLOOD AMYLASE INCREASED (19 patients)
OEDEMA (19 patients)
INFECTIOUS PLEURAL EFFUSION (19 patients)
DYSPEPSIA (19 patients)
COMA HEPATIC (19 patients)
HEART RATE INCREASED (18 patients)
HYPERTENSIVE CRISIS (18 patients)
MYALGIA (18 patients)
ECZEMA (18 patients)
URINARY TRACT INFECTION (18 patients)
NEUROMYOPATHY (18 patients)
MEDICAL DEVICE COMPLICATION (18 patients)
DIVERTICULITIS (18 patients)
OSTEOMYELITIS (18 patients)
CEREBRAL ATROPHY (18 patients)
CEREBRAL VENTRICLE DILATATION (18 patients)
DIABETIC FOOT INFECTION (18 patients)
NECK PAIN (18 patients)
OLIGURIA (17 patients)
GASTROINTESTINAL DISORDER (17 patients)
HAEMATOCHEZIA (17 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (17 patients)
HYPOTHYROIDISM (17 patients)
TRANSAMINASES INCREASED (17 patients)
OROPHARYNGEAL PAIN (17 patients)
CHRONIC MYELOID LEUKAEMIA (17 patients)
NEOPLASM PROGRESSION (17 patients)
METASTASES TO ADRENALS (16 patients)
LYMPHOCYTE COUNT DECREASED (16 patients)
INTERNATIONAL NORMALISED RATIO INCREASED (16 patients)
MULTI-ORGAN FAILURE (16 patients)
FEAR (16 patients)
PANCREATIC CARCINOMA (16 patients)
HYPERSOMNIA (16 patients)
EPILEPSY (16 patients)
SUBARACHNOID HAEMORRHAGE (16 patients)
METASTASES TO LUNG (16 patients)
TACHYCARDIA (16 patients)
MUSCULAR WEAKNESS (16 patients)
KLEBSIELLA SEPSIS (16 patients)
MYOCARDIAL ISCHAEMIA (16 patients)
DYSGEUSIA (16 patients)
LUNG INFECTION (16 patients)
FAECES DISCOLOURED (16 patients)
PAIN OF SKIN (16 patients)
SPINAL FRACTURE (16 patients)
PANIC REACTION (16 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.

Recent FactMed Activity for SORAFENIB (RAF KINASE INHIBITOR)

Issue	Description / Topic	Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about EMOTIONAL DISTRESS and SORAFENIB (RAF KINASE INHIBITOR), post it here. You may receive a response from a fellow patient - or a leading expert in the field.

Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking SORAFENIB (RAF KINASE INHIBITOR), post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.

Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in SORAFENIB (RAF KINASE INHIBITOR). This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.

We are currently accepting registration for SORAFENIB (RAF KINASE INHIBITOR) experts. If you are a healthcare provider experienced in prescribing SORAFENIB (RAF KINASE INHIBITOR), please register here.